Keywords: Astellas, Licensing, Tolmar, Eligard, Prostate cancer
Astellas in licensing deal with Tolmar for Eligard in additional markets
Article | 18 January 2011
Japanese drug major Astellas (TYO: 4503) says its European subsidiary has acquired a license for the commercialization of Colorado, USA-based Tolmar& ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
